Vagal nerve activity predicts overall survival in metastatic pancreatic cancer, mediated by inflammation

被引:73
作者
De Couck, Marijke [1 ]
Marechal, Raphael [2 ]
Moorthamersc, Sofie [3 ]
Van Laethem, Jean-Luc [2 ]
Gidron, Yori [3 ]
机构
[1] Vrije Univ Brussel, Mental Hlth & Wellbeing Res Grp, Fac Med & Pharm, 103 Laarbeeklaan, B-1090 Brussels, Belgium
[2] Univ Libre Bruxelles, Dept Gastroenterol, GI Canc Unit, Erasme Univ Hosp, 808 Route Lennik, B-1070 Brussels, Belgium
[3] Vrije Univ Brussel, Fac Med & Pharm, 103 Laarbeeklaan, B-1090 Brussels, Belgium
关键词
Autonomic nervous system; Vagus nerve; Pancreatic cancer; Neuroimmuno-modulation; Inflammation; HEART-RATE-VARIABILITY; VAGUS NERVE; CELLS; HOPELESSNESS; STIMULATION; BIOFEEDBACK; MORTALITY; INVASION; STRESS; LUNG;
D O I
10.1016/j.canep.2015.11.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent research findings suggest neuro-modulation of tumors. Finding new modifiable prognostic factors paves the way for additional treatments, which is crucial in advanced cancer, particularly pancreatic cancer. This study examined the relationship between vagal nerve activity, indexed by heart rate variability (HRV), and overall survival (OS) in patients (N = 272) with advanced pancreatic cancer. A "historical prospective" design was employed, where vagal activity and other confounders were retroactively obtained from medical charts at diagnosis, and subsequent OS was examined. HRV was obtained from 10 sec ECGs near diagnosis. Levels of C-reactive protein (CRP) were measured as an inflammatory marker. OS and survival date were obtained from medical charts and the Belgian national registry. Patients with high HRV (>20 msec) survived on average more than double the days (133.5) than those with low HRV (64.0). In a multivariate cox regression, higher initial HRV was significantly correlated with lower risk of death, independent of confounders including age and cancer treatments. This relationship was statistically mediated (accounted for) by CRP levels. Importantly, in patients who lived up to one month from diagnosis only, HRV was unrelated to CRP, while in patients surviving longer, HRV was significantly inversely related to CRP (r = -0.20, p < 0.05). These results are in line with possible vagal nerve protection in a fatal cancer, and propose that the mechanism may involve neuroimmuno-modulation. Future studies must test whether vagal nerve activation may help patients with advanced cancers. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 35 条
[1]   Interleukin-1 may link helplessness-hopelessness with cancer progression: A proposed model [J].
Argaman, M ;
Gidron, Y ;
Ariad, S .
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2005, 12 (03) :161-170
[2]   Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin [J].
Borovikova, LV ;
Ivanova, S ;
Zhang, MH ;
Yang, H ;
Botchkina, GI ;
Watkins, LR ;
Wang, HC ;
Abumrad, N ;
Eaton, JW ;
Tracey, KJ .
NATURE, 2000, 405 (6785) :458-462
[3]  
Camm AJ, 1996, CIRCULATION, V93, P1043
[4]  
CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1
[5]   Positive psychological well-being and mortality: A quantitative review of prospective observational studies [J].
Chida, Yoichi ;
Steptoe, Andrew .
PSYCHOSOMATIC MEDICINE, 2008, 70 (07) :741-756
[6]   Norms of vagal nerve activity, indexed by Heart Rate Variability, in cancer patients [J].
De Couck, M. ;
Gidron, Y. .
CANCER EPIDEMIOLOGY, 2013, 37 (05) :737-741
[7]   The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients [J].
De Couck, Marijke ;
van Brummelen, David ;
Schallier, Denis ;
De Greve, Jacques ;
Gidron, Yori .
ONCOLOGY REPORTS, 2013, 30 (05) :2435-2441
[8]   You may need the vagus nerve to understand pathophysiology and to treat diseases [J].
De Couck, Marijke ;
Mravec, Boris ;
Gidron, Yori .
CLINICAL SCIENCE, 2012, 122 (7-8) :323-328
[9]  
Dekker JM, 1997, AM J EPIDEMIOL, V145, P899, DOI 10.1093/oxfordjournals.aje.a009049
[10]   Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters [J].
Entschladen, F ;
Drell, TL ;
Lang, K ;
Joseph, J ;
Zaenker, KS .
LANCET ONCOLOGY, 2004, 5 (04) :254-258